PuraPharm Corporation Limited provided earnings guidance for the year ending December 31, 2021. For the period, the company expects net loss of not more than HKD 140 million for the year ended 31 December 2021, as compared to the audited consolidated net profit of approximately HKD 31.7 million recorded for the year ended 31 December 2020. Based on the information currently available, the Board believes that the expected net loss in Fiscal Year 2021 is mainly attributable to the following one-off and non-cash fair value and impairment losses: due to the reduction of expected future output of raw Chinese herbs as a result of the lower level of soil fertility and sunlight as well as the changes in management personnel in the plantation business, the Group is expected to record a fair value loss on biological assets related to its plantation segment of not more than HKD 53.0 million during Fiscal Year 2021; and as a result of the change in business plan and strategy in the plantation business, changes in management personnel of the plantation business and the aforementioned fair value loss of the Group's biological assets, an impairment loss of goodwill of approximately HKD 67.3 million in respect of the Group's plantation segment is expected to be recorded.